HTA Methodology Shifts & Digital Health Integration

MarcusWelcome to the Access Brief — your daily briefing on the convergence of evidence, policy, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, the tension between innovation assessment and system sustainability is really hitting a new inflection point lately.

MarcusSame here. We're looking at the evolution of HTA methodologies for cell and gene therapies — how agencies are recalibrating for one-time treatments. Then the IRA's impact on real-world evidence generation — a fundamental shift in data strategies. Patient-reported outcomes in rare disease value assessments — the growing emphasis on patient voice. And digital health integration challenges — fitting these into traditional HTA structures.

SaraThat third one about PROs in rare diseases resonates deeply. The budget impact question there is one the field hasn't fully worked out yet, especially when trials are small and endpoints are surrogate-driven.

MarcusExactly. Let's get into it.

MarcusStarting with cell and gene therapies, HTA bodies are fundamentally rethinking cost-effectiveness models. Traditional annualized cost calculations don't capture the one-time nature of these interventions, leading to methodological friction. We're seeing emerging frameworks incorporating long-term modeling and risk-adjusted thresholds.

SaraThat's fair, though I think payers would see it differently. The part that gives me pause is the equity dimension — how do these methodologies address ultra-rare conditions when the evidence base is inherently limited? The opportunity cost argument becomes acute when budgets are constrained.

MarcusWhat strikes me about that is the parallel development of managed entry agreements. These are becoming essential bridges between innovative pricing models and traditional HTA assessments. The question is whether they're sustainable at scale.

SaraI'd push back slightly on that. Managed entry agreements work for high-profile therapies but create administrative burden for smaller players. The operational complexity often outweighs the theoretical benefits for rare disease developers.

MarcusThat connects to something I keep coming back to: the need for standardized outcome sets across jurisdictions. Without that, we're seeing inconsistent value assessments that fragment market access.

SaraRight, and from the payer side, that fragmentation is unsustainable. We need harmonized endpoints that capture both clinical and economic value without reinventing the wheel for every new therapy.

MarcusShifting to the IRA's impact on real-world evidence generation. The Act is fundamentally reshaping how companies approach post-marketing data collection, particularly for drugs entering negotiation. There's an accelerated push for RWE to supplement clinical trial data.

SaraI wonder if that's the full picture though. The regulatory uncertainty around RWE acceptance creates a real dilemma for manufacturers. The evidence requirements aren't always aligned with the negotiation timelines, leading to strategic paralysis.

MarcusThat's one read — I'd frame it slightly differently as a catalyst for innovation in data generation. We're seeing more adaptive trial designs and pragmatic trials specifically tailored to IRA timelines. The pressure is driving methodological advancement.

SaraWhat's striking here is the budget implication. Generating robust RWE requires significant investment, which ultimately gets factored into pricing. It's a circular challenge where evidence costs directly impact affordability.

MarcusExactly, and that's why early engagement with HTA bodies is becoming non-negotiable. The companies that are proactively aligning their RWE strategies with payer expectations are gaining traction in negotiations.

SaraThe part that gives me pause is the quality standard. There's a risk of generating voluminous but methodologically weak data that doesn't actually inform value assessments. The signal-to-noise ratio is a growing concern.

MarcusOn patient-reported outcomes in rare disease value assessments, HTA bodies are increasingly incorporating PROs as primary endpoints, especially when clinical outcomes are hard to measure. This reflects a broader patient-centric shift.

SaraThat's fair, though I think payers would see it differently. The challenge is establishing the reliability of PROs in small populations. The variability in patient-reported data can undermine cost-effectiveness calculations when sample sizes are limited.

MarcusWhat strikes me about that is the emergence of digital PROs (dPROs) as potential solutions. They offer more granular, real-world data that could address some of these reliability concerns, particularly in rare disease contexts.

SaraI'd push back slightly on that. The digital divide in rare disease populations is real. Not all patients have access to smartphones or reliable internet, which could introduce selection bias in dPRO data collection.

MarcusThat connects to something I keep coming back to: the need for mixed-methods approaches. Combining traditional PROs with qualitative insights from patient advocacy groups creates a more comprehensive value story.

SaraRight, and from the payer side, that comprehensive approach is essential when making reimbursement decisions for therapies with limited evidence. The patient perspective can't be an afterthought in rare disease assessments.

MarcusFinally, integrating digital health technologies into HTA frameworks. The rapid proliferation of apps, wearables, and AI-driven tools is creating significant methodological challenges for HTA bodies.

SaraI wonder if that's the full picture though. The interoperability issues between different digital platforms create data silos that make comprehensive assessment nearly impossible. HTA bodies lack the infrastructure to aggregate this fragmented data.

MarcusThat's one read — I'd frame it slightly differently as an opportunity to rethink evidence generation entirely. Digital tools could enable continuous outcome monitoring that captures real-world effectiveness in ways traditional trials can't.

SaraWhat's striking here is the cost-effectiveness question. How do you value a therapy that requires ongoing digital support? The total cost of ownership includes both the intervention and the digital infrastructure, which complicates traditional economic modeling.

MarcusExactly, and that's why we're seeing early examples of value-based agreements tied to digital endpoints. The key is defining meaningful metrics that reflect both clinical utility and system impact.

SaraThe part that gives me pause is the regulatory uncertainty. HTA bodies are still developing methodologies for digital health, creating a moving target for manufacturers. This uncertainty can delay patient access to potentially transformative tools.

SaraA lot to think about today. I'll be watching how HTA bodies operationalize these methodological shifts, particularly for digital health and rare disease PROs.

MarcusSame — and for me the thread running through today is the accelerating need for flexible evidence frameworks that can accommodate both scientific innovation and system sustainability. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.